-
1
-
-
84928774156
-
The future of immune checkpoint therapy
-
Sharma P, Allison JP., The future of immune checkpoint therapy. Science. 2015;348:56–61. doi: 10.1126/science.aaa8172
-
(2015)
Science
, vol.348
, pp. 56-61
-
-
Sharma, P.1
Allison, J.P.2
-
2
-
-
85017451727
-
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
-
Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60–65. doi: 10.1038/nature22079
-
(2017)
Nature
, vol.545
, pp. 60-65
-
-
Huang, A.C.1
Postow, M.A.2
Orlowski, R.J.3
Mick, R.4
Bengsch, B.5
Manne, S.6
Xu, W.7
Harmon, S.8
Giles, J.R.9
Wenz, B.10
-
3
-
-
84874845333
-
Agonistic CD40 antibodies and cancer therapy
-
Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19:1035–1043. doi: 10.1158/1078-0432.CCR-12-2064
-
(2013)
Clin Cancer Res
, vol.19
, pp. 1035-1043
-
-
Vonderheide, R.H.1
Glennie, M.J.2
-
4
-
-
84941615057
-
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
-
Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015;125:3377–3383. doi: 10.1172/JCI80012
-
(2015)
J Clin Invest
, vol.125
, pp. 3377-3383
-
-
Buchbinder, E.1
Hodi, F.S.2
-
5
-
-
84927130807
-
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
-
Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205–214. doi: 10.1016/j.cell.2015.03.030
-
(2015)
Cell
, vol.161
, pp. 205-214
-
-
Sharma, P.1
Allison, J.P.2
-
6
-
-
0034141468
-
Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb
-
Ito D, Ogasawara K, Iwabuchi K, Inuyama Y, Onoe K. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J Immunol. 2000;164:1230–1235
-
(2000)
J Immunol
, vol.164
, pp. 1230-1235
-
-
Ito, D.1
Ogasawara, K.2
Iwabuchi, K.3
Inuyama, Y.4
Onoe, K.5
-
7
-
-
33947506186
-
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
-
Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876–883. doi: 10.1200/JCO.2006.08.3311
-
(2007)
J Clin Oncol
, vol.25
, pp. 876-883
-
-
Vonderheide, R.H.1
Flaherty, K.T.2
Khalil, M.3
Stumacher, M.S.4
Bajor, D.L.5
Hutnick, N.A.6
Sullivan, P.7
Mahany, J.J.8
Gallagher, M.9
Kramer, A.10
-
8
-
-
84874605864
-
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
-
Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616–622. doi: 10.1200/JCO.2012.44.6112
-
(2013)
J Clin Oncol
, vol.31
, pp. 616-622
-
-
Ribas, A.1
Kefford, R.2
Marshall, M.A.3
Punt, C.J.4
Haanen, J.B.5
Marmol, M.6
Garbe, C.7
Gogas, H.8
Schachter, J.9
Linette, G.10
-
9
-
-
32644467549
-
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
-
Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968–8977. doi: 10.1200/JCO.2005.01.109
-
(2005)
J Clin Oncol
, vol.23
, pp. 8968-8977
-
-
Ribas, A.1
Camacho, L.H.2
Lopez-Berestein, G.3
Pavlov, D.4
Bulanhagui, C.A.5
Millham, R.6
Comin-Anduix, B.7
Reuben, J.M.8
Seja, E.9
Parker, C.A.10
-
10
-
-
61449090474
-
Phase I/II trial of tremelimumab in patients with metastatic melanoma
-
Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009;27:1075–1081. doi: 10.1200/JCO.2008.19.2435
-
(2009)
J Clin Oncol
, vol.27
, pp. 1075-1081
-
-
Camacho, L.H.1
Antonia, S.2
Sosman, J.3
Kirkwood, J.M.4
Gajewski, T.F.5
Redman, B.6
Pavlov, D.7
Bulanhagui, C.8
Bozon, V.A.9
Gomez-Navarro, J.10
-
11
-
-
78549256115
-
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
-
Ruter J, Antonia SJ, Burris HA, 3rd, Huhn RD, Vonderheide RH. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther. 2010;10:983–993. doi: 10.4161/cbt.10.10.13251
-
(2010)
Cancer Biol Ther
, vol.10
, pp. 983-993
-
-
Ruter, J.1
Antonia, S.J.2
Burris, H.A.3
Huhn, R.D.4
Vonderheide, R.H.5
-
12
-
-
84877805593
-
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
-
Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013;2:e23033. doi: 10.4161/onci.23033
-
(2013)
Oncoimmunology
, vol.2
, pp. e23033
-
-
Vonderheide, R.H.1
Burg, J.M.2
Mick, R.3
Trosko, J.A.4
Li, D.5
Shaik, M.N.6
Tolcher, A.W.7
Hamid, O.8
-
13
-
-
79953154967
-
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans
-
Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612–1616. doi: 10.1126/science.1198443
-
(2011)
Science
, vol.331
, pp. 1612-1616
-
-
Beatty, G.L.1
Chiorean, E.G.2
Fishman, M.P.3
Saboury, B.4
Teitelbaum, U.R.5
Sun, W.6
Huhn, R.D.7
Song, W.8
Li, D.9
Sharp, L.L.10
-
14
-
-
84922254940
-
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma
-
Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C, Nathanson KL, Schuchter LM, Kalos M, et al. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol Res. 2014;2:1051–1058. doi: 10.1158/2326-6066.CIR-14-0154
-
(2014)
Cancer Immunol Res
, vol.2
, pp. 1051-1058
-
-
Bajor, D.L.1
Xu, X.2
Torigian, D.A.3
Mick, R.4
Garcia, L.R.5
Richman, L.P.6
Desmarais, C.7
Nathanson, K.L.8
Schuchter, L.M.9
Kalos, M.10
-
15
-
-
84949936992
-
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma
-
Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA, et al. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol. 2015;26:2483–2490. doi: 10.1093/annonc/mdv387
-
(2015)
Ann Oncol
, vol.26
, pp. 2483-2490
-
-
Nowak, A.K.1
Cook, A.M.2
McDonnell, A.M.3
Millward, M.J.4
Creaney, J.5
Francis, R.J.6
Hasani, A.7
Segal, A.8
Musk, A.W.9
Turlach, B.A.10
-
16
-
-
34247327043
-
An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model
-
Hunter TB, Alsarraj M, Gladue RP, Bedian V, Antonia SJ. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model. Scand J Immunol. 2007;65:479–486. doi: 10.1111/j.1365-3083.2007.01927.x
-
(2007)
Scand J Immunol
, vol.65
, pp. 479-486
-
-
Hunter, T.B.1
Alsarraj, M.2
Gladue, R.P.3
Bedian, V.4
Antonia, S.J.5
-
17
-
-
70749083844
-
Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
-
Carpenter EL, Mick R, Ruter J, Vonderheide RH. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med. 2009;7:93. doi: 10.1186/1479-5876-7-93
-
(2009)
J Transl Med
, vol.7
, pp. 93
-
-
Carpenter, E.L.1
Mick, R.2
Ruter, J.3
Vonderheide, R.H.4
-
18
-
-
79959746703
-
The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice
-
Gladue RP, Paradis T, Cole SH, Donovan C, Nelson R, Alpert R, Gardner J, Natoli E, Elliott E, Shepard R, et al. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol Immunother. 2011;60:1009–1017. doi: 10.1007/s00262-011-1014-6
-
(2011)
Cancer Immunol Immunother
, vol.60
, pp. 1009-1017
-
-
Gladue, R.P.1
Paradis, T.2
Cole, S.H.3
Donovan, C.4
Nelson, R.5
Alpert, R.6
Gardner, J.7
Natoli, E.8
Elliott, E.9
Shepard, R.10
-
19
-
-
33947223664
-
Prospect of targeting the CD40 pathway for cancer therapy
-
Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007;13:1083–1088. doi: 10.1158/1078-0432.CCR-06-1893
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1083-1088
-
-
Vonderheide, R.H.1
-
20
-
-
0030996214
-
The CD40 ligand. At the center of the immune universe?
-
Grewal IS, Flavell RA. The CD40 ligand. At the center of the immune universe? Immunol Res. 1997;16:59–70
-
(1997)
Immunol Res
, vol.16
, pp. 59-70
-
-
Grewal, I.S.1
Flavell, R.A.2
-
21
-
-
84888086049
-
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma
-
Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013. doi: 10.1158/1078-0432.CCR-13-1320
-
(2013)
Clin Cancer Res
-
-
Beatty, G.L.1
Torigian, D.A.2
Chiorean, E.G.3
Saboury, B.4
Brothers, A.5
Alavi, A.6
Troxel, A.B.7
Sun, W.8
Teitelbaum, U.R.9
Vonderheide, R.H.10
-
22
-
-
84961290760
-
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
-
Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015;25:208–224. doi: 10.1038/cr.2015.3
-
(2015)
Cell Res
, vol.25
, pp. 208-224
-
-
Hannani, D.1
Vetizou, M.2
Enot, D.3
Rusakiewicz, S.4
Chaput, N.5
Klatzmann, D.6
Desbois, M.7
Jacquelot, N.8
Vimond, N.9
Chouaib, S.10
-
23
-
-
84928917822
-
Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma
-
Patt D, Chen T-T, Berman DM, Wolchok JD
-
Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen T-T, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–1894. doi: 10.1200/JCO.2014.56.2736
-
(2015)
J Clin Oncol
, vol.33
, pp. 1889-1894
-
-
Schadendorf, D.1
Hodi, F.S.2
Robert, C.3
Weber, J.S.4
Margolin, K.5
Hamid, O.6
-
24
-
-
84936147067
-
combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. doi: 10.1056/NEJMoa1504030
-
(2015)
N Engl J Med
, vol.373
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
Grob, J.J.4
Cowey, C.L.5
Lao, C.D.6
Schadendorf, D.7
Dummer, R.8
Smylie, M.9
Rutkowski, P.10
-
25
-
-
33750533981
-
Giving blood: a new role for CD40 in tumorigenesis
-
Bergmann S, Pandolfi PP. Giving blood: a new role for CD40 in tumorigenesis. J Exp Med. 2006;203:2409–2412. doi: 10.1084/jem.20061754
-
(2006)
J Exp Med
, vol.203
, pp. 2409-2412
-
-
Bergmann, S.1
Pandolfi, P.P.2
-
26
-
-
79954579274
-
Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody
-
Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17:2270–2280. doi: 10.1158/1078-0432.CCR-10-2888
-
(2011)
Clin Cancer Res
, vol.17
, pp. 2270-2280
-
-
Fransen, M.F.1
Sluijter, M.2
Morreau, H.3
Arens, R.4
Melief, C.J.5
-
27
-
-
85011955241
-
Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
-
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6:664–679. doi: 10.1158/2159-8290.CD-16-0040
-
(2016)
Cancer Discov
, vol.6
, pp. 664-679
-
-
Teachey, D.T.1
Lacey, S.F.2
Shaw, P.A.3
Melenhorst, J.J.4
Maude, S.L.5
Frey, N.6
Pequignot, E.7
Gonzalez, V.E.8
Chen, F.9
Finklestein, J.10
-
28
-
-
84926525215
-
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
-
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–377. doi: 10.1038/nature14292
-
(2015)
Nature
, vol.520
, pp. 373-377
-
-
Twyman-Saint Victor, C.1
Rech, A.J.2
Maity, A.3
Rengan, R.4
Pauken, K.E.5
Stelekati, E.6
Benci, J.L.7
Xu, B.8
Dada, H.9
Odorizzi, P.M.10
-
29
-
-
84983372582
-
Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma
-
Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res. 2015;3:399–411. doi: 10.1158/2326-6066.CIR-14-0215
-
(2015)
Cancer Immunol Res
, vol.3
, pp. 399-411
-
-
Winograd, R.1
Byrne, K.T.2
Evans, R.A.3
Odorizzi, P.M.4
Meyer, A.R.5
Bajor, D.L.6
Clendenin, C.7
Stanger, B.Z.8
Furth, E.E.9
Wherry, E.J.10
-
30
-
-
0029851283
-
A note on quantifying follow-up in studies of failure time
-
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Controlled Clinical Trials. 1996;17:343–346
-
(1996)
Controlled Clinical Trials
, vol.17
, pp. 343-346
-
-
Schemper, M.1
Smith, T.L.2
|